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Summary
Objective: To characterize the indications of pregnant women who sought the Fetal 
Medicine Services of the Hospital das Clínicas, at the Medical School of the Universidade 
de São Paulo for performing invasive diagnostic procedures, and to evaluate the results 
of fetal karyotypes and their pregnancies. Methods: A retrospective and observational 
study on pregnant women who underwent chorionic villus sampling (CVS), amniocen-
tesis, and cordocentesis in the period from February, 2005 to December, 2009. Other 
diagnostic or therapeutic procedures were not included. The result of pregnancy was ob-
tained by consulting patient electronic records, medical records, and/or telephone call. 
Results: 713 procedures were performed (113 CVS, 340 amniocenteses, and 260 cordo-
centeses). The main indication for performing invasive procedures was the presence of 
structural changes in fetuses, followed by increased values of nuchal translucency, and 
advanced maternal age. Fetal karyotype was altered in 186 cases (26.1%). The18 trisomy 
was the commonest aneuploidy followed by the 21 trisomy, X monosomy, and 13 tri-
somy. There were 4.9% cases of miscarriage, 25.7% cases of stillborn infants, and 13% 
cases of neonatal deaths. Eight pregnant women opted for legally induced abortion. 99% 
of pregnant women whose fetuses did not present abnormalities and presented normal 
fetal karyotype had infants who were born alive.
Uniterms: Karyotype; chorionic villus sampling; fetal blood; fetus.
©2012 Elsevier Editora Ltda. All rights reserved.
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IntroductIon
Pre-natal screening for aneuploidy started in the 1970s, 
with maternal age as its main indication1.
The risk of chromosomal abnormalities increases with 
the maternal age. In a study that evaluated approximately 
89,000 classical amniocenteses, pregnant women aged 35 
years or over presented more chromosomal changes than 
women aged less than 35 years. The frequencies of trisomy 
21, trisomy 18, and trisomy 13 for women aged over 35 
years were1/100, 1/454, and 1/1438, respectively. Con-
versely, the frequencies for women aged under 35 years 
were 1/591, 1/2862, and 1/4651 for the same aneuploidies2. 
The use of maternal age of 35 years or more as a cut-off 
point for indicating fetal karyiotype research presents a 
sensitivity of approximately 30%. 
In the 1990s, biochemical screening in the second tri-
mester started by evaluating alpha-fetoprotein, beta cho-
rionic gonadotropin (β-HCG), and unconjugated estriol 
in maternal plasma, with a sensitivity of 60% and a false-
positive rate of 5% for trisomy 213. With the improvement 
of ultrasound devices and equipment, screening was ad-
vanced to the first trimester by nuchal translucency evalu-
ation. The detection rate for Down syndrome through 
nuchal translucency is 77%, with a false-positive rate of 
5%4. The association of nuchal translucency with protein 
dosage in maternal blood, maternal serum free-beta-cho-
rionic gonadotropin (free β-HCG) and pregnancy-associ-
ated plasma protein-A (PAPP-A) raises the sensitivity to 
90%, with the same false-positive rate5,6. Another benefit 
of combined screening is the reduction of cases with in-
dication for invasive procedure, reducing the exposure of 
pregnant women to the risks of such a procedure7.
Morphological ultrasound scan can be also used for 
screening chromosomal anomalies in the second trimes-
ter of gestation. Some abnormalities can also be related to 
aneuploidy, such as ventriculomegaly, facial cleft, cardi-
opathy, diaphragmatic hernia, nephropathy, omphalocele, 
shortened limbs, and club-foot8,9.
The definite diagnosis of chromosomal abnormality in 
the antenatal period is only possible by performing inva-
sive procedures and analysis of the fetal tissue or its compo-
nents, such as trophoblast, amniotic fluid, and fetal blood10.
Chorionic villus sampling (CVS) presents a risk of total 
fatal loss varying from 2.3% to 3.7%11-13. Those rates take 
into account the early procedure, and as a consequence, 
the presence in this group of chromosomally altered fe-
tuses that would evolve to spontaneous abortion. The ad-
vantage of this examination is the early gestational age of 
diagnosis. The main disadvantage is confined placental 
mosaicism, which occurs in approximately 1% of the cases 
and causes the need to repeat the procedure in another 
environment (amniotic fluid or fetal blood)14,15. Classical 
amniocentesis offers a risk of fetal loss of 0.3% to 1.0%16-18. 
Cordocentesis is a procedure that allows for the evaluation 
of fetal karyotype, besides anemia diagnosis, infections, 
and fetal hemoglobinopathies. This procedure presents a 
1.4% risk of fetal loss19.
At the Obstetrics Department of the Hospital das 
Clínicas of the Medical School at the Universidade de São 
Paulo (HCFMUSP), the Fetal Medicine Services is a refer-
ence for cases of fetuses with abnormalities or increased 
risk for aneuploidies. The service performs invasive pro-
cedures for fetal karyotype studies in cases diagnosed at 
the service and in cases referred to from external services. 
However, data regarding fetal procedures, karyotype re-
sults, and evolution of pregnant women who underwent 
an invasive procedure have not yet been published, and 
national data are scarce. Publishing those data is relevant, 
as it represents a reference service in the city of São Paulo 
and provides useful information on advice to future preg-
nant women, at local and national level.
The main objective of this study was to characterize the 
indications of pregnant women who sought the Fetal Med-
icine Services of a tertiary center for performing invasive 
diagnostic procedures for fetal karyotype studies. Second-
ary objectives were to evaluate fetal karyotype results and 
their gestations.
methodS
A retrospective, observational, and cross-sectional study 
was performed at the Fetal Medicine Services of the Ob-
stetric Department at the HCFMUSP; the study was ap-
proved by the ethics in research committee of the institu-
tion (CaPPesq – HCFMUSP), No. 0600/09.
Pregnant women who underwent invasive procedures 
(CVS, amniocentesis, and cordocentesis) were selected in 
the period from February, 2005 to December, 2009.
Pregnant women were referred from other fetal medi-
cine services or from this institution. After genetic coun-
seling and explanation of the risks related to the proce-
dure, the pregnant woman or her legal guardian signed an 
informed consent. Before performing the invasive proce-
dure, all pregnant women underwent morphological ul-
trasonography for evaluation of fetal structure.
Only pregnant women who underwent invasive diag-
nostic procedures for fetal karyotype (CVS, amniocentesis 
and cordocentesis) were included. CVS was performed 
between 11 and 14 weeks, six days of gestation; amniocen-
tesis, from 14 weeks; and cordocentesis, from 19 weeks.
Procedures with other purposes, such as amniotic fluid 
drainage, placement of drains, and laser or punctures for 
fetal karyotype collected from other dry secretions were 
not included.
The survey of pregnant women who underwent in-
vasive procedures was performed by consulting the da-
tabank from the Information System of Official Reports 
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Indication
CVS
(n = 113)
n (%)
Amniocentesis
(n =  340)
n (%)
Cordocentesis
(n = 260)
n (%)
Fetal malformation 26 (23.0%) 227 (66.8%) 245 (94.3%)
Increased NT 64 (56.7%) 29 (8.5%) 03 (1.2%)
Maternal age 20 (17.7%) 49 (14.4%) 04 (1.5%)
Presence of ultrasonography marker in the  
2nd trimester
00 24 (7.1%) 03 (1.2%)
Culture media failure 00 02 (0.6%) 04 (1.5%)
Antecedent aneuploidy 02 (1.7%) 05 (1.5%) 00
Parents bearing chromosopathy 01 (0.9%) 02 (0.6%) 00
Anxiety 00 01 (0.3%) 00
Anterior child with malformation 00 01 (0.3%) 00
Mosaicism in amniotic fluid 00 00 01 (0.4%)
CVS, chorionic villus sampling; NT, nuchal translucency.
Table 1 – Indications for performing invasive procedures for fetal karyotype research. HCFMUSP, 2005 to 2009
on Obstetrics and Gynecology (Sistema Informatizado de 
Laudos em Obstetrícia e Ginecologia — SILOG), which is 
used by the Fetal Medicine Services for ultrasonography 
scans report, invasive procedures, and fetal and gestation 
scan results. Postnatal results were obtained by consulting 
paper-based medical records in the HCFMUSP and in SI-
LOG, and/or by telephone call to patients.
Population features evaluated were: patients’ age; indi-
cations for performing invasive procedures; number and 
type of procedures performed (CVS, amniocentesis, and 
cordocentesis); results of fetal karyotype; and evolution 
of gestations (legally and non-legally induced abortion; 
miscarriage defined as gestation loss up to twenty weeks 
of pregnancy; stillborn, defined as birth of fetus dead after 
twenty weeks of pregnancy; and neonatal deaths, defined 
as death until 28 days post-birth)20.
Numerical variables were described as maximum, 
minimum, average and standard deviation, or median. For 
the categorical variables, simple and relative frequencies 
were used.
reSultS
In the period studied, 713 diagnostic invasive procedures 
were performed as follows: 113 CVS, 340 amniocentesis, 
and 260 cordocentesis. Table 1 describes indications for 
diagnostic invasive procedures performed during the pe-
riod studied.
Regarding CVS, maternal age for performing the pro-
cedure varied from 15 to 45 years, with an average of 32.4 
(± 7.7) years. The average gestational age was 13.4 (± 1.3) 
weeks of pregnancy.
In the group of pregnant women who underwent am-
niocentesis, maternal age for performing the procedure var-
ied from 14 to 47 years, with an average of 30.7 (± 8.2) years. 
The gestational age for performing the procedures 
varied from 14.3 to 34 weeks, with an average of 
20.1 (± 3.6) weeks. Among the cases of amniocen-
tesis, a case of maternal death was observed 22 days 
after the procedure, in a case of high risk to the 
mother’s life with a diagnosis of sickle-cell anemia.
Regarding cordocentesis, maternal age varied 
from 13 to 48 years, with an average of 28 (± 7.5). 
The average gestational age was of 27.1 (± 3.6) weeks 
of pregnancy.
From those pregnant women who underwent 
cordocentesis, 53.5% (139/260 had children born 
alive, 24.6% (64/260) had stillborn children, 20.8% 
(54/260) had neonatal death, and 1.6% (3/260) opt-
ed for legally induced abortion.
Table 2 shows the results of fetal karyotypes 
from the cases submitted to invasive procedures at 
the Fetal Medicine Services of the Obstetrics De-
partment at the HCFMUSP in the period studied. 
The result of pregnancies is shown in Table 3.
 Table 4 describes the main fetal abnormalities 
in fetuses evolving to intrauterine death.
dIScuSSIon
The majority of patients who were referred to this 
Fetal Medicine Services presented morphological 
fetal changes, considering this was the main reason 
for performing fetal karyotype invasive procedures, 
representing 69.8% of indications.
The indication rates for performing the pro-
cedures differ from the medical literature, taking 
into account that structural abnormalities rep-
resent up to 12% of cases in most studies8,14,21,22. 
Such a difference among indications may be due 
Mario Kohatsu et al.
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Procedure/karyotype
CVS
n (%)
Amniocentesis
n (%)
Cordocentesis
n (%)
Total
n (%)
Normal 77 (68.2%) 214 (63%) 187 (67.3%) 478 (67%)
13 trisomy 03 (2.6%) 12 (3.5%) 12 (4.6%) 27 (3.8%)
18 trisomy 09 (8.0%) 30 (8.8%) 19 (7.3%) 58 (8.1%)
21 trisomy 10 (8.8%) 20 (5.9%) 14 (5.4%) 44 (6.2%)
X monosomy 06 (5.3%) 24 (7.1%) 04 (6.2%) 34 (4.8%)
Triploidy 0 04 (1.2%) 01 (0.4%) 05 (0.7%)
Other aneuploidy 01 (0.9%) 08 (2.3%) 10 (3.8%) 19 (2.7%)
Culture media failure 07 (6.2%) 28 (8.2%) 13 (5.0%) 48 (6.7%)
CVS, chorionic villus sampling.
Table 2 – Results of fetal karyotypes of the cases submitted to diagnostic invasive procedures.
Procedure/result
CVS 
113
n (%)
Amniocentesis
340
n (%)
Cordocentesis
260
n (%)
Total
713
n (%)
Total intrauterine death 39 (34.5%) 125 (36.8%) 67 (25.8%) 231(32.4%)
Total intrauterine death associated with 
fetal malformation or abnormal karyotype
39 (34.5%) 124 (36.4%) 67 (25.8%) 230 (32.2%)
Legally induced abortion 01 (0.9%) 04 (1.2%) 03 (1.2%) 8 (1.1%)
Neonatal death 03 (2.6%) 36 (10.6%) 52 (20%) 91 (12.8%)
Born alive 71 (62.9%) 179 (52.6%) 141 (54.2%) 391 (54.8%)
Total intrauterine death, the sum of intrauterine deaths associated with fetal malformation or abnormal karyotype and legally induced abortion; 
otal intrauterine death associated with fetal malformation or abnormal karyotype, total intrauterine deaths with malformation or abnormal fetal 
karyotype including legally induced abortions of altered fetuses; CVS, chorionic villus sampling.
Table 3 – Results of pregnant women who underwent invasive procedures for fetal karyotype study
Procedure/fetal malformation CVS Amniocentesis Cordocentesis Total
Hidropsy 10 23 9 42
Nervous system 3 17 15 35
Pulmonary 0 2 2 4
Heart 3 5 4 12
Digestive system 0 1 1 2
Abdominal wall defect 1 4 3 8
Urinary system 2 3 4 9
Skeletal dysplasia 1 7 3 11
Total 20 62 41 123
CVS, chorionic villus sampling.
Table 4 – Description of malformation by fetal system of the cases evolving to intrauterine death
to factors such as the non-existence of public policy for 
screening chromosomal abnormalities, difficulty of ac-
cess to diagnostic examination services, patients fearful 
of adverse results after performing the procedures, and 
impossibility or limitation to treatment after certain di-
agnoses. In addition, this study was performed in a ter-
tiary center where cases of abnormalities are referred to, 
many times in an advanced stage of pregnancy. Maternal 
age 35 years or over was, in the past, the main indication 
for invasive procedures in developed countries. Presently, 
this indication has been substituted by the result of indi-
vidual risk on screening tests in the first trimester by nu-
chal translucency measurements, sometimes combined 
with biochemical screening (free β-HCG and PAPP-A). 
In the present study, maternal age of 35 years or over 
represented 10.2% of indications and ultrasonography 
screening from the first trimester, is described by the in-
creased translucency in 13.5%, describes the second and 
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the third commonest indications respectively. The other 
indications observed (antecedent aneuploidies, parents 
bearing chromosomopathies, and anterior child bear-
ing abnormalities) presented frequencies similar to the 
medical literature23,24.
In this study, it was also possible to observe a differ-
ence in the number of chromosomal abnormalities found 
(27.1%), a very high rate compared to other studies, which 
presented chromosomal abnormality rates up to 14%8,14,22. 
This rate cannot be extended to the general population, 
since this is a reference service where patients are referred 
to for possible diagnosis and counseling.
Another difference observed is the culture media fail-
ure rate of 6.7% (48/713). The medical literature reports 
rates lower than 1.0%14,15,25,26. This rate may be related to 
technical collection problems, as this is a teaching hospital, 
but it also indicates the need to review laboratory routines. 
Among the cases of culture media failure, in only six cases 
was a new puncture performed. Five cases of intrauterine 
death were observed among those cases of culture media 
failure, occurring in the time interval between the punc-
ture and the return of fetal karyotype results. In 41 cases, 
the failure occurred in analyzing fetal karyotype in amni-
otic fluid or cordocentesis. The advanced gestational age 
in these procedures, approximately 20 weeks for amnio-
centesis and 27 weeks for cordocentesis, a period in which 
pregnant women initially feel fetal movements, may have 
influenced the decision to not perform a new puncture, for 
fear of a greater loss in advanced gestational age. 
Adverse results, such as miscarriage, stillborn, and 
neonatal death also presented high rates when compared 
to rates in other studies: 4.9%, 25.7%, and 13% respec-
tively. This was probably due to the presence of a great 
proportion of fetuses bearing chromosomal abnormali-
ties and anomalies, besides the non-existence of a law for 
induced abortion in case of malformed fetuses. In 11 Eu-
ropean countries, induced abortion by fetal indication is 
allowed regardless of the gestational age27. In medical liter-
ature, miscarriage rates have been described from 0.35% to 
2.58%; of stillborns, from 0.35% to 1.0%; and of neonatal 
death, from 0% to 8.33%14,17,21,28-30. Antsaklis et al.30, in fe-
tuses presenting ultrasonography changes who underwent 
cordocentesis, reported 15.5% of intrauterine deaths and 
8.33% neonatal deaths. These rates are lower than those 
observed in the present study, even though only fetuses 
bearing ultrasonography changes were included, probably 
demonstrating the severe condition in which such infants 
are referred to the service.
Knowledge of fetal karyotype has allowed counseling 
to pregnant women. In some cases, pregnant women were 
allowed to make decisions they deemed more adequate 
for their gestation, opting for legally induced abortion, 
obtained by preliminary order in cases of chromosomal 
abnormalities incompatible with extra-uterine life. For 
pregnant women whose fetuses had severe abnormalities 
incompatible with life, chromosomal changes, or when 
they presented the need for psychological support, psycho-
logical counseling had was offered. The knowledge of fetal 
karyotype also allowed for appropriate delivery planning.
In the study, a patient who underwent amniocentesis 
with 16 weeks and five days of pregnancy died. The in-
dication for performing the procedure was the presence 
of omphalocele and fetal cardiopathy. The karyotype 
result was 46, XY. The patient was hospitalized after 15 
days, and discharged after a week of antibiotic therapy 
for pneumonia. Death occurred 22 days after the amnio-
centesis procedure. The maternal death was probably not 
related to the invasive procedure, as the pregnant woman 
had sickle cell anemia and had been on in other occa-
sions during this pregnancy due to algic crisis, needing 
blood transfusion. Deaths related to invasive procedures 
take place after maternal sepsis, starting up to 30 hours 
after the procedure31; this fact does not appear to be re-
lated to this patient.
Among pregnant women with normal fetal karyotype 
and no structural changes, the gestational results were 
superior, presenting a survival rate of 99% (95/96) among 
all of the cases submitted to invasive procedures.
concluSIon
Fetal karyotype is an important diagnostic examination 
that should be offered to all patients after genetic counsel-
ing and screening test. This invasive procedure presents a 
risk of pregnancy loss; however, the present study dem-
onstrates that the majority of fetal losses was related to a 
subjacent fetal condition (presence of fetal abnormalities 
and aneuploidies). Only one case evolved to intrauterine 
death with no fetal abnormality or abnormal karyotype. 
HCFMUSP still considers malformation and abnormali-
ties as the main indication for fetal karyotype research, 
and such cases are referred to in advanced gestational age, 
which may be responsible for the higher number of cordo-
centesis (36.4%) for evaluation of fetal karyotype.
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